A Phase 2 interventional study of Fluticasone furoate (FF) (100 mcg) and Vilanterol (VI) (25 mcg) in Asthma, sponsored by GlaxoSmithKline. Completed at 1 site in New Zealand. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-08-28.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing fluticasone furoate in Asthma — none open to participants now, 3 under way, 2 of them phase 3. fluticasone furoate · Asthma.
Among the 40 studies testing fluticasone furoate in Asthma, this one is the 29th largest by enrollment, is the only one that started in 2016, is one of 12 in phase 2, and was the 30th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →None of the 40 studies testing fluticasone furoate in Asthma is open now. The open studies under Asthma, anywhere →
fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 102 across the 40 interventional studies. Of the 35 that completed or were terminated, 22 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 40 have an industry lead sponsor. The 4 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
262 studies in Asthma by GlaxoSmithKline: 7 open now, 12 under way, 7 of them phase 3. Of 240 finished, 132 (55%) have results posted.
Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 177th largest by enrollment of the 238 interventional ones that give a count, is one of 9 that started in 2016, is one of 59 in phase 2, and was the 200th registered.
GlaxoSmithKline’s Asthma studies by the year they started, since 1999.
1 of the studies testing fluticasone furoate in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
Add it to your calendar (.ics) → With an account.
Among the 40 studies testing fluticasone furoate in Asthma, from their registry updates:
Among GlaxoSmithKline’s 262 in Asthma:
This tab as a report to print or save as PDF → With an account.
For asthmatic subjects, a combination of inhaled corticosteroid (FF) and long-acting beta2 receptor agonist (VI) is recommended for use (once daily) and fraction of exhaled nitric oxide (FeNO) is a non-invasive airway inflammation marker.
In this randomised, double blind, placebo-controlled, two-period, crossover repeat dose study, the duration of action of fluticasone furoate (FF) will be determined by monitoring the return of FeNO levels to baseline, following the treatment with FF/vilanetrol (VI) in asthmatic subjects.
Subjects who meet the eligibility criteria will participate in the following two treatment periods: FF/VI 100/25 mcg once-daily and placebo once-daily. Approximately 28 subjects will be enrolled in order to achieve 24 evaluable subjects. A 2-week treatment period will be followed by a 21-day monitoring/washout period before crossing over to the next treatment period. Total duration of each subject will be a maximum of 21 weeks. FeNO will be monitored up to 21 days after treatment with FF/VI together with FEV1 (up to 7 days).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Tubal ligation Hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal occlusion Hysterectomy Bilateral Oophorectomy
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive FF/VI 100/25 mcg each morning (once daily) from Day 1 to Day 14, followed by a 21-day monitoring/washout period
Drug: Fluticasone furoate (FF) (100 mcg) · Drug: Vilanterol (VI) (25 mcg)
Subjects will receive placebo each morning (once daily) from Day 1 to Day 14, followed by a 21-day monitoring/washout period
Drug: Placebo
First blister strip contains FF blended with lactose, 100 mcg per blister
Second blister strip contains vilanterol blended with lactose and magnesium stearate, 25 mcg per blister
Matching placebo will have two blister strips, identical in appearance to the inhaler containing active study medication; one containing lactose and the second strip containing lactose and magnesium stearate
Change From Baseline in Fraction of Exhaled Nitric Oxide (FeNO) Over Time Following the Cessation of Repeat Dose Treatment With FF/VI
FeNO is non-invasive marker of airway inflammation in asthma participants. It was measured by the participants, using Niox Vero device at AM (pre-dose) and PM on Day -7 and all way through Day 29 of each TP. The FeNO measurements were done over time following stop of repeat dose treatment with FF/VI. Change from Baseline was measured as ratio of post-dose visit value to Baseline value. Baseline was defined as Day 1(Pre-dose). Subject level Baseline defined as the mean of Baseline across periods for each participant. Period level Baseline defined as the difference between the Baseline and subject level Baseline for each period and each participant. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Summary of ratio from Baseline for exhaled nitric oxide reported as Geometric mean and Geometric coefficient of Variation. NA indicates data was not available.
Time frame: Baseline and up to Day 29 in each treatment period
Change From Baseline in FeNO Over the FF/VI Treatment Period
In participants with asthma the FeNO is a non-invasive marker of airway inflammation. The FeNO was measured by the participants AM (pre-dose) and PM on Day -7 and all the way through Day 29 of each treatment period. The measurements were recorded using Niox Vero device provided at the site. These FeNO measurements were done throughout the treatment period. Change from Baseline was measured by the value at post-dose visit minus the Baseline value. Baseline was defined as Day 1(Pre-dose). Subject level Baseline is defined as the mean of Baseline across periods for each participant. Period level Baseline is defined as the difference between the Baseline and subject level Baseline for each period and each participant. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). NA indicates data was not available.
Time frame: Baseline and up to Day 29 in each treatment period
Change From Baseline in Peak Expiratory Flow (PEF) During Treatment and Following Cessation of Repeat Dose Treatment With FF/VI
The PEF is a lung function evaluation assessed using a PEF meter. It was defined as the maximum amount of air exhaled during forced exhalation with lungs fully inflated. For PEF measurements the best of the 3 recordings were recorded AM and PM (i.e every 12 hours), from Day-7 through to Day 29 of TP1, and then from Day 1 of TP2 through to the (29). Change from Baseline was measured by the value at post-dose visit minus the Baseline value. Baseline was defined as Day 1(Pre-dose). Subject level Baseline is defined as the mean of Baseline across periods for each participant. Period level Baseline is defined as the difference between the Baseline and subject level Baseline for each period and each participant. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). NA indicates data was not available.
Time frame: Baseline and up to Day 29 in TP1; Baseline and up to follow up (Day 29) in TP2
Change From Baseline in Forced Expiratory Volume in One Second (FEV1) Pre-treatment and for up to 7 Days After Cessation of Repeat Dose Treatment With FF/VI
FEV1 is defined as the maximal amount of air which can be exhaled forcefully in one second. Three technically acceptable FEV1 measurements were made using a spirometer, and were measured on pre-dose on Day 1, taken pre-dose on Day 14 and every morning and evening until Day 19, and in the morning on Day 21. Change from Baseline was measured by the value at post-dose visit minus the Baseline value. Baseline was defined as Day 1(Pre-dose). Subject level Baseline is defined as the mean of Baseline across periods for each participant. Period level Baseline is defined as the difference between the Baseline and subject level Baseline for each period and each participant.
Time frame: Baseline every morning and evening until Day 21 of each treatment period
This was a randomized, double blind, placebo-controlled, two-period, crossover repeat dose study in adult participants with asthma. The study was conducted from 29 April 2016 to 21 February 2017, at a single site in New Zealand.
| Milestone | Fluticasone Furoate/Vilanterol (FF/VI) Followed by Placebo | Placebo Followed by FF/VI |
|---|---|---|
| Started | 14 | 13 |
| Completed | 14 | 13 |
| Not completed | 0 | 0 |
| Milestone | Fluticasone Furoate/Vilanterol (FF/VI) Followed by Placebo | Placebo Followed by FF/VI |
|---|---|---|
| Started | 14 | 13 |
| Completed | 14 | 13 |
| Not completed | 0 | 0 |
| Milestone | Fluticasone Furoate/Vilanterol (FF/VI) Followed by Placebo | Placebo Followed by FF/VI |
|---|---|---|
| Started | 14 | 13 |
| Completed | 14 | 13 |
| Not completed | 0 | 0 |
FeNO is non-invasive marker of airway inflammation in asthma participants. It was measured by the participants, using Niox Vero device at AM (pre-dose) and PM on Day -7 and all way through Day 29 of each TP. The FeNO measurements were done over time following stop of repeat dose treatment with FF/VI. Change from Baseline was measured as ratio of post-dose visit value to Baseline value. Baseline was defined as Day 1(Pre-dose). Subject level Baseline defined as the mean of Baseline across periods for each participant. Period level Baseline defined as the difference between the Baseline and subject level Baseline for each period and each participant. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). Summary of ratio from Baseline for exhaled nitric oxide reported as Geometric mean and Geometric coefficient of Variation. NA indicates data was not available.
| Ratio of exhaled Nitric Oxide | Placebo | FF/VI 100/25mcg |
|---|---|---|
| Day 1, AM (n=27,27) | 1.042 ± 31.5499 | 0.371 ± 47.3672 |
| Day 1, PM (n=27,27) | 0.985 ± 26.4785 | 0.321 ± 51.5233 |
| Day 2, AM (n=27,27) | 1.012 ± 27.3017 | 0.373 ± 71.6824 |
| Day 2, PM (n=27,27) | 0.957 ± 26.3328 | 0.346 ± 52.6225 |
| Day 3, AM (n=27,27) | 0.987 ± 24.6102 | 0.442 ± 60.8203 |
| Day 3, PM (n=27,27) | 0.922 ± 23.6705 | 0.417 ± 51.1903 |
| Day 4, AM (n=27,27) | 1.007 ± 34.9235 | 0.536 ± 60.5532 |
| Day 4, PM (n=27,27) | 0.857 ± 23.7972 | 0.484 ± 48.1593 |
| Day 5, AM (n=27,27) | 0.834 ± 24.4572 | 0.515 ± 53.5926 |
| Day 5, PM (n=26,26) | 0.734 ± 27.1308 | 0.473 ± 46.6144 |
| Day 6, AM (n=26,26) | 0.794 ± 31.5924 | 0.525 ± 50.7361 |
| Day 6, PM (n=24,26) | 0.783 ± 30.8200 | 0.470 ± 43.8128 |
| Day 7, AM (n=27,27) | 0.826 ± 31.4676 | 0.484 ± 49.0454 |
| Day 7, PM (n=25,25) | 0.774 ± 32.7473 | 0.487 ± 49.9617 |
| Day 8, AM (n=25,27) | 0.830 ± 40.7773 | 0.554 ± 47.5854 |
| Day 8, PM (n=27,26) | 0.834 ± 30.4030 | 0.545 ± 42.1101 |
| Day 9, AM (n=27,27) | 0.935 ± 35.7583 | 0.594 ± 45.0429 |
| Day 9, PM (n=27,27) | 0.924 ± 32.1314 | 0.607 ± 46.3872 |
| Day 10, AM (n=24,26) | 1.022 ± 34.4740 | 0.658 ± 41.3710 |
| Day 10, PM (n=27,27) | 0.989 ± 35.1066 | 0.660 ± 41.4832 |
| Day 11, AM (n=26,26) | 1.092 ± 37.7142 | 0.756 ± 40.9942 |
| Day 11, PM (n=27,27) | 1.029 ± 28.6618 | 0.723 ± 45.9281 |
| Day 12, AM (n=27,27) | 1.028 ± 29.9667 | 0.717 ± 42.8654 |
| Day 12, PM (n=27,27) | 1.004 ± 28.5673 | 0.691 ± 43.1839 |
| Day 13, AM (n=27,25) | 1.068 ± 34.0090 | 0.744 ± 38.4939 |
| Day 13, PM (n=25,25) | 0.955 ± 40.2945 | 0.739 ± 39.5506 |
| Day 14, AM (n=26,27) | 1.008 ± 45.5319 | 0.770 ± 43.7613 |
| Day 14, PM (n=25,26) | 0.955 ± 45.5768 | 0.634 ± 76.0516 |
| Day 15, AM (n=26,26) | 0.977 ± 51.5523 | 0.731 ± 40.4602 |
| Day 15, PM (n=25,25) | 0.940 ± 42.3660 | 0.700 ± 48.1949 |
| Day 16, AM (n=26,27) | 1.029 ± 51.1876 | 0.727 ± 44.7703 |
| Day 16, PM (n=26,27) | 1.019 ± 38.1690 | 0.718 ± 50.7656 |
| Day 17, AM (n=25,26) | 1.049 ± 40.1495 | 0.770 ± 44.3320 |
| Day 17, PM (n=18,16) | 0.967 ± 38.4731 | 0.765 ± 59.4286 |
| Day 18, AM (n=17,14) | 0.935 ± 39.0474 | 0.724 ± 54.2082 |
| Day 18, PM (n=14,10) | 0.926 ± 39.2470 | 0.619 ± 58.6249 |
| Day 19, AM (n=14,10) | 1.015 ± 42.2250 | 0.722 ± 51.2962 |
| Day 19, PM (n=12,6) | 0.911 ± 30.6911 | 0.571 ± 48.1910 |
| Day 20, AM (n=12,6) | 0.958 ± 43.0056 | 0.667 ± 45.5449 |
| Day 20, PM (n=7,5) | 0.828 ± 39.6562 | 0.588 ± 54.7676 |
| Day 21, AM (n=7,6) | 0.892 ± 35.8531 | 0.743 ± 54.8750 |
| Day 21, PM (n=7,5) | 0.934 ± 40.4076 | 0.637 ± 63.2223 |
| Day 22, AM (n=6,5) | 0.845 ± 45.8754 | 0.705 ± 82.0353 |
| Day 22, PM (n=6,5) | 0.822 ± 43.0801 | 0.622 ± 75.8988 |
| Day 23, AM (n=7,5) | 0.925 ± 51.4896 | 0.749 ± 76.0176 |
| Day 23, PM (n=2,1) | 0.898 ± 116.9108 | 1.000 ± NA |
| Day 24, AM (n=2,1) | 0.914 ± 130.0375 | 1.144 ± NA |
| Day 24, PM (n=1,1) | 0.671 ± NA | 0.911 ± NA |
| Day 25, AM (n=1,0) | 0.548 ± NA | — |
| Day 26, PM (n=0,1) | — | 0.989 ± NA |
| Day 28, AM (n=0,1) | — | 1.044 ± NA |
| Day 28, PM (n=0,1) | — | 0.767 ± NA |
| Day 29, AM (n=0,1) | — | 0.911 ± NA |
In participants with asthma the FeNO is a non-invasive marker of airway inflammation. The FeNO was measured by the participants AM (pre-dose) and PM on Day -7 and all the way through Day 29 of each treatment period. The measurements were recorded using Niox Vero device provided at the site. These FeNO measurements were done throughout the treatment period. Change from Baseline was measured by the value at post-dose visit minus the Baseline value. Baseline was defined as Day 1(Pre-dose). Subject level Baseline is defined as the mean of Baseline across periods for each participant. Period level Baseline is defined as the difference between the Baseline and subject level Baseline for each period and each participant. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). NA indicates data was not available.
| Parts per billion | Placebo | FF/VI 100/25mcg |
|---|---|---|
| Day 1, AM (n=27,27) | 1.9 ± 24.39 | -63.3 ± 45.47 |
| Day 1, PM (n=27,27) | -0.5 ± 24.55 | -68.5 ± 49.07 |
| Day 2, AM (n=27,27) | 1.3 ± 27.67 | -63.5 ± 53.63 |
| Day 2, PM (n=27,27) | -3.1 ± 24.64 | -66.1 ± 48.26 |
| Day 3, AM (n=27,27) | -0.8 ± 25.07 | -56.6 ± 53.97 |
| Day 3, PM (n=27,27) | -7.9 ± 21.18 | -59.8 ± 47.32 |
| Day 4, AM (n=27,27) | 1.2 ± 33.27 | -48.6 ± 50.54 |
| Day 4, PM (n=27,27) | -11.6 ± 17.93 | -51.5 ± 42.12 |
| Day 5, AM (n=27,27) | -15.3 ± 22.49 | -48.9 ± 47.09 |
| Day 5, PM (n=26,26) | -22.1 ± 19.45 | -54.0 ± 45.00 |
| Day 6, AM (n=26,26) | -17.6 ± 24.37 | -47.1 ± 42.19 |
| Day 6, PM (n=24,26) | -19.4 ± 25.76 | -54.0 ± 43.96 |
| Day 7, AM (n=27,27) | -15.4 ± 24.26 | -50.0 ± 43.19 |
| Day 7, PM (n=25,25) | -19.9 ± 25.92 | -46.4 ± 42.73 |
| Day 8, AM (n=25,27) | -14.2 ± 30.00 | -42.7 ± 44.14 |
| Day 8, PM (n=27,26) | -15.3 ± 24.70 | -46.1 ± 40.39 |
| Day 9, AM (n=27,27) | -5.7 ± 29.23 | -40.1 ± 37.45 |
| Day 9, PM (n=27,27) | -5.3 ± 23.53 | -38.7 ± 40.36 |
| Day 10, AM (n=24,26) | 4.1 ± 27.86 | -31.6 ± 31.50 |
| Day 10, PM (n=27,27) | 3.8 ± 28.99 | -32.8 ± 37.47 |
| Day 11, AM (n=26,26) | 12.8 ± 31.82 | -23.8 ± 39.65 |
| Day 11, PM (n=27,27) | 6.2 ± 34.03 | -26.4 ± 41.33 |
| Day 12, AM (n=27,27) | 3.1 ± 24.79 | -25.7 ± 36.64 |
| Day 12, PM (n=27,27) | 1.3 ± 25.08 | -29.4 ± 37.19 |
| Day 13, AM (n=27,25) | 8.3 ± 35.47 | -23.3 ± 30.09 |
| Day 13, PM (n=25,25) | -1.6 ± 38.12 | -26.2 ± 39.97 |
| Day 14, AM (n=26,27) | 4.7 ± 45.42 | -23.5 ± 38.84 |
| Day 14, PM (n=25,26) | -3.4 ± 42.26 | -30.9 ± 43.69 |
| Day 15, AM (n=26,26) | -1.6 ± 47.88 | -25.8 ± 37.76 |
| Day 15, PM (n=25,25) | -3.7 ± 49.33 | -27.9 ± 43.14 |
| Day 16, AM (n=26,27) | 3.7 ± 48.00 | -26.7 ± 43.16 |
| Day 16, PM (n=26,27) | 4.5 ± 37.40 | -26.6 ± 43.37 |
| Day 17, AM (n=25,26) | 6.1 ± 42.81 | -20.9 ± 39.31 |
| Day 17, PM (n=18,16) | -8.5 ± 29.54 | -19.6 ± 48.58 |
| Day 18, AM (n=17,14) | -7.5 ± 32.10 | -27.3 ± 44.36 |
| Day 18, PM (n=14,10) | -6.2 ± 23.93 | -38.3 ± 42.90 |
| Day 19, AM (n=14,10) | -2.8 ± 27.47 | -30.7 ± 50.03 |
| Day 19, PM (n=12,6) | -9.3 ± 24.19 | -52.2 ± 49.82 |
| Day 20, AM (n=12,6) | 0.1 ± 27.71 | -40.2 ± 46.27 |
| Day 20, PM (n=7,5) | -8.7 ± 21.68 | -59.0 ± 63.82 |
| Day 21, AM (n=7,6) | -6.6 ± 24.08 | -32.7 ± 56.23 |
| Day 21, PM (n=7,5) | -3.0 ± 25.83 | -51.2 ± 58.37 |
| Day 22, AM (n=6,5) | -7.5 ± 27.54 | -37.0 ± 66.25 |
| Day 22, PM (n=6,5) | -11.5 ± 27.52 | -51.8 ± 63.96 |
| Day 23, AM (n=7,5) | -0.6 ± 29.53 | -37.0 ± 71.04 |
| Day 23, PM (n=2,1) | -0.5 ± 54.45 | 0.0 ± NA |
| Day 24, AM (n=2,1) | 2.0 ± 59.40 | 13.0 ± NA |
| Day 24, PM (n=1,1) | -24.0 ± NA | -8.0 ± NA |
| Day 25, AM (n=1,0) | -33.0 ± NA | — |
| Day 26, PM (n=0,1) | — | -1.0 ± NA |
| Day 28, AM (n=0,1) | — | 4.0 ± NA |
| Day 28, PM (n=0,1) | — | -21.0 ± NA |
| Day 29, AM (n=0,1) | — | -8.0 ± NA |
The PEF is a lung function evaluation assessed using a PEF meter. It was defined as the maximum amount of air exhaled during forced exhalation with lungs fully inflated. For PEF measurements the best of the 3 recordings were recorded AM and PM (i.e every 12 hours), from Day-7 through to Day 29 of TP1, and then from Day 1 of TP2 through to the (29). Change from Baseline was measured by the value at post-dose visit minus the Baseline value. Baseline was defined as Day 1(Pre-dose). Subject level Baseline is defined as the mean of Baseline across periods for each participant. Period level Baseline is defined as the difference between the Baseline and subject level Baseline for each period and each participant. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). NA indicates data was not available.
| Liter per minute | Placebo | FF/VI 100/25mcg |
|---|---|---|
| Day 1, AM (n=27,27) | -1.0 ± 67.11 | 44.6 ± 55.54 |
| Day 1, PM (n=27,27) | 17.4 ± 69.59 | 54.5 ± 63.23 |
| Day 2, AM (n=27,27) | 5.1 ± 61.50 | 32.4 ± 55.35 |
| Day 2, PM (n=27,27) | 16.6 ± 74.02 | 37.2 ± 53.42 |
| Day 3, AM (n=27,27) | 9.0 ± 58.49 | 24.3 ± 58.56 |
| Day 3, PM (n=27,27) | 20.4 ± 69.10 | 47.3 ± 52.80 |
| Day 4, AM (n=26,26) | 18.3 ± 61.63 | 28.8 ± 54.42 |
| Day 4, PM (n=27,27) | 36.0 ± 85.62 | 43.9 ± 56.01 |
| Day 5, AM (n=27,26) | 19.7 ± 61.28 | 25.4 ± 49.86 |
| Day 5, PM (n=26,27) | 21.5 ± 75.94 | 30.9 ± 49.67 |
| Day 6, AM (n=25,26) | -0.4 ± 69.89 | 4.1 ± 61.63 |
| Day 6, PM (n=24,26) | 11.3 ± 75.26 | 28.5 ± 52.75 |
| Day 7, AM (n=27,27) | 11.5 ± 71.97 | 17.0 ± 55.89 |
| Day 7, PM (n=24,26) | 11.8 ± 75.33 | 21.8 ± 55.70 |
| Day 8, AM (n=27,27) | -1.6 ± 73.80 | 2.6 ± 51.94 |
| Day 8, PM (n=27,27) | 13.1 ± 61.79 | 9.1 ± 56.68 |
| Day 9, AM (n=27,26) | -7.2 ± 80.69 | -14.7 ± 74.06 |
| Day 9, PM (n=27,27) | 9.1 ± 73.71 | -1.7 ± 58.12 |
| Day 10, AM (n=26,26) | -19.6 ± 76.63 | -19.9 ± 68.55 |
| Day 10, PM (n=27,26) | -1.7 ± 84.64 | 12.6 ± 52.16 |
| Day 11, AM (n=26,27) | -12.8 ± 74.84 | -12.3 ± 56.24 |
| Day 11, PM (n=27,27) | 15.8 ± 76.76 | -7.3 ± 63.12 |
| Day 12, AM (n=24,26) | -11.0 ± 83.14 | -23.5 ± 64.35 |
| Day 12, PM (n=26,27) | -2.4 ± 71.17 | -5.9 ± 66.19 |
| Day 13, AM (n=27,26) | -20.6 ± 77.50 | -35.1 ± 67.19 |
| Day 13, PM (n=25,26) | 17.0 ± 104.76 | -13.0 ± 61.78 |
| Day 14, AM (n=25,25) | -31.5 ± 77.48 | -13.6 ± 65.25 |
| Day 14, PM (n=25,27) | -0.8 ± 76.69 | -1.6 ± 58.26 |
| Day 15, AM (n=25,27) | -17.4 ± 59.88 | -20.4 ± 58.86 |
| Day 15, PM (n=25,25) | -15.0 ± 67.65 | -7.8 ± 64.72 |
| Day 16, AM (n=25,26) | -27.0 ± 66.70 | -30.2 ± 75.78 |
| Day 16, PM (n=26,26) | -8.1 ± 74.86 | 0.7 ± 60.72 |
| Day 17, AM (n=26,26) | -23.4 ± 73.32 | -4.7 ± 65.85 |
| Day 17, PM (n=18,16) | 10.6 ± 86.60 | 8.7 ± 62.33 |
| Day 18, AM (n=17,14) | -14.2 ± 79.96 | 3.8 ± 71.50 |
| Day 18, PM (n=14,10) | -8.9 ± 90.25 | 29.6 ± 64.62 |
| Day 19, AM (n=14,10) | -11.4 ± 91.61 | -0.1 ± 70.24 |
| Day 19, PM (n=12,6) | 2.3 ± 102.76 | 27.7 ± 61.49 |
| Day 20, AM (n=12,6) | -8.5 ± 81.09 | -10.5 ± 71.92 |
| Day 20, PM (n=7,5) | -27.7 ± 46.03 | 26.6 ± 49.22 |
| Day 21, AM (n=7,6) | -43.3 ± 56.85 | 17.8 ± 78.20 |
| Day 21, PM (n=6,4) | -16.7 ± 73.86 | -19.8 ± 32.62 |
| Day 22, AM (n=5,5) | -48.4 ± 40.28 | -11.0 ± 103.22 |
| Day 22, PM (n=6,5) | -56.8 ± 46.23 | -2.0 ± 91.29 |
| Day 23, AM (n=6,5) | -15.0 ± 50.62 | 11.4 ± 53.62 |
| Day 23, PM (n=2,1) | -53.0 ± 1.41 | 1.0 ± NA |
| Day 24, AM (n=2,1) | -23.0 ± 25.46 | 74.0 ± NA |
| Day 24, PM (n=1,1) | -50.0 ± NA | 15.0 ± NA |
| Day 25, AM (n=1,0) | -31.0 ± NA | — |
| Day 26, PM (n=0,1) | — | -62.0 ± NA |
| Day 27, AM (n=0,1) | — | 82.0 ± NA |
| Day 28, AM (n=0,1) | — | -42.0 ± NA |
| Day 29, AM (n=0,1) | — | 6.0 ± NA |
FEV1 is defined as the maximal amount of air which can be exhaled forcefully in one second. Three technically acceptable FEV1 measurements were made using a spirometer, and were measured on pre-dose on Day 1, taken pre-dose on Day 14 and every morning and evening until Day 19, and in the morning on Day 21. Change from Baseline was measured by the value at post-dose visit minus the Baseline value. Baseline was defined as Day 1(Pre-dose). Subject level Baseline is defined as the mean of Baseline across periods for each participant. Period level Baseline is defined as the difference between the Baseline and subject level Baseline for each period and each participant.
| Liter | Placebo | FF/VI 100/25mcg |
|---|---|---|
| Day 1, AM | 0.036 ± 0.4169 | 0.361 ± 0.3135 |
| Day 1, PM | 0.180 ± 0.3105 | 0.383 ± 0.3151 |
| Day 2, AM | 0.073 ± 0.3953 | 0.331 ± 0.2739 |
| Day 2,PM | 0.200 ± 0.3902 | 0.369 ± 0.3166 |
| Day 3,AM | 0.084 ± 0.3668 | 0.271 ± 0.2967 |
| Day 3,PM | 0.213 ± 0.3840 | 0.319 ± 0.3256 |
| Day 4, AM | 0.092 ± 0.3870 | 0.241 ± 0.2913 |
| Day 4, PM | 0.221 ± 0.4187 | 0.301 ± 0.3163 |
| Day 5, AM | 0.197 ± 0.3375 | 0.207 ± 0.2498 |
| Day 7, AM | 0.124 ± 0.3753 | 0.102 ± 0.3317 |
| Day 21, AM | 0.082 ± 0.3210 | 0.004 ± 0.2670 |
Collected over All the Serious adverse events (SAEs) and Adverse events (AEs) from Day 1 to upto Day 35 in each period (Total 70 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/27 (0%) | 0/27 (0%) | 10/27 (37%) |
| FF/VI 100/25mcg | 0/27 (0%) | 0/27 (0%) | 14/27 (51.9%) |
| Event | Placebo | FF/VI 100/25mcg |
|---|---|---|
| Viral upper respiratory tract infectionInfections and infestations | 5/27 | 7/27 |
| Back painMusculoskeletal and connective tissue disorders | 2/27 | 0/27 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 0/27 | 2/27 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/27 | 2/27 |
| OrchitisInfections and infestations | 1/27 | 0/27 |
| Urinary tract infectionInfections and infestations | 1/27 | 0/27 |
| Viral pharyngitisInfections and infestations | 0/27 | 1/27 |
| Neck painMusculoskeletal and connective tissue disorders | 0/27 | 1/27 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/27 | 1/27 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/27 | 1/27 |
| Age, Continuous(Years) | Total (Placebo+FF/VI 100/25mcg) |
|---|---|
| Mean | 24.5 ± 8.14 |
| Sex: Female, Male(Participants) | Total (Placebo+FF/VI 100/25mcg) |
|---|---|
| Female | 10 |
| Male | 17 |
| Race/Ethnicity, Customized(Participants) | Total (Placebo+FF/VI 100/25mcg) |
|---|---|
| White | 21 |
| Asian and White | 1 |
| Native Hawaiin or other Pacific Islander and White | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2016 to primary completion in Feb 2017, 9 months.
Results were first posted in Aug 2018, 1 year 6 months after primary completion.
Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 9 months is below that.
Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fluticasone furoate · Vilanterol